Abstract:AIM:To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC).METHODS:Thirty-two patients with extrahepatic metastasis of HCC after local treatment were prospectively enrolled. The CapeOx regimen consisted of capecitabine 1000 mg/m(2) taken orally twice daily on days 1-14, and oxaliplatin was administered at a total dose of 100 mg/m(2) on day 1. The treatment was repeated every 3 wk until disease progression or unaccetablle toxicity. Efficacy and safety were assessable for all enrolled patients. The primary objective of this study was to assess the overall response rate. The secondary objectives were to evaluate the overall survival (OS), the time to tumor progression (TTP) and the toxicity profile of the combined strategy. TTP and OS were assessed by the Kaplan-Meier method and differences between the curves were analyzed using the log-rank test. The statistical software SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, United States) was used for statistical analysis. All P values were 2-tailed, with statistical significance defined by P ≤ 0.05.RESULTS:Thirty-two patients were assessable for efficacy and toxicity. The median follow-up duration was 15 mo (range, 12-20 mo). At the cut-off date of March 31, 2012, 27 patients died due to tumor progression and one patient died of myocardial infarction. Four patients were still alive (three patients with disease progression). OR was 21.9% (n = 7), the stabilization rate was 40.6% (n = 13), and the disease control rate was 62.5%. The responses lasted from 4 to 19 mo (median, 6 mo). Median TTP was 4.2 mo (95%CI: 2.5-7.4), and the median OS time was 9.2 mo (95%CI: 6.5-17.8). The 1-year survival rate was 43.6% (95%CI: 29.0-66.0). In a multivariate analysis, OS was significantly longer in patients with a Child-Pugh class A compared with class B patients (P = 0.014), with a median OS of 10.1 mo vs 5.4 mo, and there were trends towards longer OS (P = 0.065) in patients without portal vein tumor thrombosis. There were no significant effects of age, gender, performance status, cirrhosis, metastatic sites, and level of alpha fetoprotein (AFP) or hepatitis B virus-DNA on OS. Among the 22 patients with elevated AFP levels at baseline (≥ 400 ng/mL), the level fell by more than 50% during treatment in 6 patients (27.3%). The most frequent treatment-related grade 3 to 4 toxicities included leucopenia/neutropenia, transient elevation of aminotransferases, hand-foot syndrome and fatigue.CONCLUSION:CapeOx showed modest anti-tumor activity in metastatic HCC. However, the manageable toxicity profile and the encouraging disease control rate deserve further study for these patients.

P-0224 Addition of Cetuximab to Oxaliplatin-Based Chemotherapy on Liver and Spleen Size and Thrombocytopenia in Patients with Metastatic Colorectal Cancer

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (clime Study)

Cetuximab plus Oxaliplatin-Based Chemotherapy for Metastatic Colorectal Cancer: a Systematic Review and Meta-Analysis

Early Tumor Shrinkage As Predictor of Outcome in Colorectal Liver Metastases Treated with Cetuximab Plus Chemotherapy

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells During Treatment of Colorectal Cancer

Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.

Clinical research on oxaliplatin or irinotecan plus capecitabine for colorectal liver metastasis treatment

Tumor Response and Secondary Resectability of Colorectal Liver Metastases Following Cetuximab with Chemotherapy: A Randomized, Controlled Study

Capecitabine but Not 5-FU Worsened Hepatosplenomegaly and Liver Function when Used with Oxaliplatin and Cetuximab As First-Line Treatment in K-ras Wild-Type Metastatic Colorectal Cancer.

Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab.

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases.

Efficacy of Capecitabine and Oxaliplatin Regimen for Extrahepatic Metastasis of Hepatocellular Carcinoma Following Local Treatments.

Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer

Clinical study on cetuximab combined with FOLFOX4 chemotherapy in treatment of metastatic colorectal cancer

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Case Report: Cetuximab in Combination With Chemotherapy for the Treatment of Multifocal Hepatic Metastases From Colorectal Cancer Guided by Genetic Tests

Efficacy and Safety of Capecitabine Plus Oxaliplatin (xelox) As the Perioperative Treatment of Patients with Potentially Resectable Liver-Only Metastases from Colorectal Cancer: A Single Arm, Open-Label, Multicenter Phase Ii Trial (ml22298; Nct00997685).

Right- and Left-Sided Colorectal Cancers Respond Differently to Cetuximab

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

Combination Chemotherapy of Oxaliplatin and Capecitabine in Patients with Metastatic Colorectal Cancer: a Pilot Study